Tricida, Inc. (TCDA) Misled Shareholders About the Viability of its Clinical Trial and Efficacy of its Lead Drug Candidate   Tricida conducted a single Phase 3 study for veverimer and

Virgin Galactic Holdings, Inc. (SPCE) Made Misstatements Regarding Its Internal Control Over Financial Reporting Virgin Galactic was formed on October 25, 2019, when the special purpose acquisition company (“SPAC”) Social

The GEO Group, Inc. (GEO) Accused of Misleading Shareholders    Between February 27, 2020 and June 16, 2020, The GEO Group touted the Company’s COVID-19 response.  Specifically, the Company stated

Clover Health Investment, Corp.  (CLOV) Misled Shareholders Ahead of Going Public            On October 6, 2020, the Company issued a press release announcing plans to become a publicly traded company

CleanSpark, Inc. (CLSK) May Have Misled Investors About its Related Party Transactions and its Customer and Contract Figures On December 31, 2020, CleanSpark issued a press release touting its achievements

Provention Bio, Inc. (PRVB) Made Misstatements Regarding its Deteriorating Financial Condition During the class period, the Company touted the FDA’s submission of a Biologics License Application (“BLA”) for teplizumab for

Washington Prime Group, Inc. (WPG) Made Misstatements Regarding its Deteriorating Financial Condition During the class period, WPG failed to disclose material adverse facts about the Company’s business, operations, and prospects. 

Provention Bio, Inc. (PRVB) Made Misstatements Regarding its Deteriorating Financial Condition During the class period, the Company touted the FDA’s submission of a Biologics License Application (“BLA”) for teplizumab for